Financials data is unavailable for this security.
Cash flow in USDView more
In 2023, Altamira Therapeutics Ltd increased its cash reserves by 9,807.44%, or 540.39k. Cash Flow from Financing totalled 1.11m or 632.06% of revenues. In addition the company used 574.55k for operations while cash from investing totalled 2.30k.
Cash flow per share | -2.42 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 2.37 |
---|---|
Tangible book value per share | 0.6333 |
More ▼
Balance sheet in USDView more
Current ratio | 0.4268 |
---|---|
Quick ratio | 0.4268 |
Total debt/total equity | 0.0677 |
---|---|
Total debt/total capital | 0.0634 |
More ▼